Skip to main content

Table 1 Patient characteristics

From: Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study

Patient characteristic Unadjusted groups IPTW Groups Matched groups
Sivelestat (n  = 87) Control (n  = 77) Standardized difference Sivelestat (n  = 162) Control (n  = 167) Standardized difference Sivelestat (n  = 31) Control (n  = 31) Standardized difference
Age, year 66.1 (17.5) 65.9 (16.2) 0.01 67.7 (16.2) 69.0 (15.8) −0.08 69.8 (15.6) 67.3 (15.3) 0.16
Male sex 57 (65.5) 50 (64.9) 0.01 104 (64.2) 114 (68.3) −0.09 21 (67.7) 19 (61.3) 0.13
Academic hospital 49 (56.3) 48 (63.3) −0.14 92 (56.8) 86 (51.8) 0.10 20 (64.5) 15 (48.4) 0.33
Hospital volume (cases)          
 Low (1–10) 37 (42.5) 43 (55.8) −0.27 73 (45.1) 70 (41.9) 0.06 15 (48.4) 14 (45.2) 0.06
 Medium (11–20) 19 (21.8) 18 (23.4) −0.04 32 (19.8) 34 (20.4) −0.01 8 (25.8) 5 (16.1) 0.28
 High (≥21) 31 (35.6) 16 (20.8) 0.33 57 (35.2) 63 (37.7) −0.05 8 (25.8) 12 (38.7) −0.28
Direct lung injury 54 (62.1) 44 (57.1) 0.10 94 (58.4) 104 (62.3) −0.08 19 (61.3) 21 (67.7) −0.13
APACHE II 22.2 (7.4) 23.5 (7.4) −0.18 23.5 (7.3) 23.3 (7.5) 0.03 23.7 (5.5) 24.0 (7.6) −0.05
SOFA score 10.1 (3.3) 11.2 (3.6) −0.32 10.7 (3.3) 10.6 (3.7) 0.03 10.8 (3.3) 10.0 (3.2) 0.25
SIRS score 2.3 (1.0) 2.4 (1.2) −0.09 2.4 (1.1) 2.4 (1.1) 0.00 2.4 (1.2) 2.5 (1.1) −0.09
MAP, mmHg 75.5 (18.3) 77.2 (15.5) −0.10 77.3 (19.1) 78.8 (17.2) −0.08 75.8 (20.1) 73.9 (14.3) 0.11
CVP, mmHg 10.7 (5.4) 9.3 (5.2) 0.26 9.8 (5.2) 9.7 (5.1) 0.02 10.5 (4.7) 9.5 (5.8) 0.19
Fluid balance on Day 0, mL 2,239 (2,228) 1,498 (1,640) 0.38 1,915 (1,977) 1,861 (1,686) 0.03 1,495 (2,267) 1,673 (2,333) −0.08
PaO2/FiO2 148.5 (73.1) 148.4 (65.6) 0 142.9 (70.2) 145.6 (63.9) −0.04 141.7 (71.1) 128.5 (60.2) 0.20
PEEP, cm/H2O 8.4 (4.9) 8.3 (4.1) 0.02 8.2 (4.6) 8.1 (3.8) 0.02 8.1 (5.0) 8.8 (4.6) −0.15
Cardiac index, L/m2 3.5 (1.4) 3.5 (1.2) 0 3.4 (1.4) 3.4 (1.1) 0.00 3.7 (1.5) 3.2 (1.0) 0.39
GEDI, mL/m2 836.9 (236.4) 784.2 (158.0) 0.26 809.9 (208.4) 805.2 (149.3) 0.03 805.9 (167.5) 761.9 (150.1) 0.28
EVLWi, mL/kg 20.0 (7.1) 17.2 (6.4) 0.41 19.1 (6.4) 19.4 (7.6) −0.04 17.1 (6.2) 18.5 (7.1) −0.21
PVPI 3.5 (1.5) 3.1 (1.2) 0.29 3.3 (1.3) 3.4 (1.3) −0.08 3.0 (0.98) 3.5 (1.5) −0.39
Corticosteroid use 38 (43.7) 26 (33.8) 0.20 62 (38.3) 69 (41.3) −0.06 12 (41.9) 10 (32.3) 0.20
Catecholamine use 58 (66.7) 59 (76.6) −0.22 117 (72.2) 113 (67.7) 0.10 23 (74.2) 23 (74.2) 0.00
Renal replacement therapy 25 (28.7) 18 (23.4) 0.12 45 (27.8) 50 (30.1) −0.05 9 (29.0) 6 (19.4) 0.23
Diuretic use 43 (49.4) 38 (49.4) 0.00 75 (46.6) 84 (50.3) −0.07 16 (51.6) 13 (41.9) 0.20
PMX use 12 (13.8) 6 (7.6) 0.20 18 (11.1) 14 (8.4) 0.09 4 (12.9) 1 (3.2) 0.36
  1. Number of patients (n) in the IPTW groups was an estimated number determined by weighting inversed probability (propensity score).
  2. APACHE, acute physiology and chronic health evaluation, CVP, central venous pressure, EVLWi, extravascular lung water index, GEDI, global end-diastolic volume index, IPTW, inverse probability of treatment weighting, PEEP, positive end-expiratory pressure, PMX, polymyxin B hemoperfusion, PVPI, pulmonary vascular permeability index, SIRS, systemic inflammatory response syndrome, SOFA, sequential organ failure assessment.